Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to $4.1 million.

  • 60 Degrees Pharmaceuticals' Cash & Equivalents rose 2469.46% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 2469.46%. This contributed to the annual value of $3.4 million for FY2024, which is 5812.6% up from last year.
  • As of Q3 2025, 60 Degrees Pharmaceuticals' Cash & Equivalents stood at $4.1 million, which was up 2469.46% from $2.0 million recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Cash & Equivalents' 5-year high stood at $4.1 million during Q3 2025, with a 5-year trough of $19070.0 in Q2 2023.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' median Cash & Equivalents value was $2.1 million (recorded in 2023), while the average stood at $1.9 million.
  • As far as peak fluctuations go, 60 Degrees Pharmaceuticals' Cash & Equivalents tumbled by 9746.22% in 2023, and later surged by 955125.2% in 2024.
  • 60 Degrees Pharmaceuticals' Cash & Equivalents (Quarter) stood at $264865.0 in 2022, then surged by 708.9% to $2.1 million in 2023, then skyrocketed by 58.13% to $3.4 million in 2024, then rose by 21.49% to $4.1 million in 2025.
  • Its Cash & Equivalents stands at $4.1 million for Q3 2025, versus $2.0 million for Q2 2025 and $3.5 million for Q1 2025.